News Daily News Menos ACV con Presiones Arteriales Menor que 140 mm Hg Animan a Rebajar los Umbrales Michael O'Riordan February 02, 2016
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for January 2016 Shelley Wood February 01, 2016
News Industry News Mast Therapeutics Announces Positive Top-Line Results From Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Conducted At Mayo Clinic January 31, 2016
News Opinion Fellow Talk Test Your Knowledge: 10 Essential Questions on the Evolution of Interventional Cardiology Sarah Elsayed, MD January 25, 2016
News Daily News Renal Denervation Trials Have Largely Fallen Victim to Unintentional Bias Todd Neale January 19, 2016
News Daily News Comparative Analysis Suggests ACE Inhibitors Equivalent to ARBs in Patients Without Heart Failure Michael O'Riordan January 19, 2016
News Daily News BP Lowering Reduces Vascular Risk Regardless of Baseline BP and Disease History Michael O'Riordan December 27, 2015
News Daily News Bajar la Presión Arterial Reduce el Riesgo Vascular con Independencia de la Presión Arterial Basal y los Antecedentes Patológicos Michael O'Riordan December 27, 2015
News Daily News For Interventional Trials, Optimal Medical Management May Entail as Much Training as New Techniques Todd Neale December 20, 2015
News Industry News Study Demonstrates i-cor® Synchronized Cardiac Assist Preserves Left Ventricular (LV) Function Compared to Continuous-Flow ECLS in Cardiogenic Shock December 15, 2015
News Daily News First-In-Human Transcatheter Tricuspid Repair Feasible But Questions Remain Michael O'Riordan December 06, 2015
News Conference News AHA 2015 SPRINT Makes Case for Even Lower BP Target in Many Hypertensive Patients Todd Neale November 08, 2015
News Industry News New Long-term Data Published in The Lancet Further Demonstrates Superiority of the CardioMEMS HF System over Standard of Care November 08, 2015
News Daily News Stroke Risk of Carotid Occlusion Appears Very Low in Contemporary Asymptomatic Patients September 29, 2015
News Industry News Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial September 18, 2015
News Conference News ESC 2015 FREEDOM Substudy: CABG, PCI Outcomes Affected by Baseline BP Yael L. Maxwell August 30, 2015
News Daily News High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease Todd Neale August 17, 2015
News Industry News Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients With Hypercholesterolemia and Hypertension July 28, 2015